Hello my dears,
Even the big biotech stocks can be fun. Especially when there is growth and a great dividend yield. That's why I'm staying invested. And enjoy the time while other investors consider whether to buy or sell Novo đ.
It's not just the small biotechs that can pull away dynamically. The breakout announcement for the Gilead Sciences share could not have been better timed
While I generally like to look at volatile small caps in the biotech sector, I focused on a "sleeping giant" in January: Gilead Sciences.
In meiner Analyse von Anfang Januar war das Setup glasklar: After years of bottoming out and a healthy consolidation at a high level, the stock delivered a wonderful breakout setup. The procyclical buy signal when the USD 128.70 mark was exceeded was immediately seized upon.
The result? Just a few weeks later, readers can look back on a share price increase of around 20 % at its peak. Gilead has clearly outperformed heavyweights such as Eli Lilly and Novo Nordisk in this period!
Number check: Fundamental confirmation
The figures published yesterday evening for the fourth quarter of 2025 underpin my bullish assessment:
- Earnings beat: With adjusted earnings of USD 1.86 per share, Gilead clearly beat expectations (consensus: USD 1.81).
- HIV dominance: Sales in the core HIV segment rose strongly. The "gamechanger" Yeztugo (HIV prevention) in particular is showing impressive momentum.
- Dividend bonus: As icing on the cake, management announced an increase in the quarterly dividend to USD 0.82. (@Dividendenopi , @SAUgut777 )
Although the share price fell briefly after a slightly more cautious outlook for 2026, it is precisely such setbacks that often offer new opportunities.
Strong HIV business: Needham raises Gilead price target to 170 US dollars
Published on 11.02.2026, 13:59
Bernstein raises price target for Gilead Sciences to $160 due to growth prospects
Published on 11.02.2026, 16:22
